Draper to Showcase Its Microphysiological Systems Capabilities at MPS World Summit 2026
CAMBRIDGE, Mass. – Draper will exhibit its flagship microphysiological system (MPS), PREDICT96, and related research results at the MPS World Summit, to be held May 26-29, 2026, at the Walter E. Washington Convention Center in Washington, D.C.
MPS World Summit is a premier forum for advancing human-relevant models and next-generation biomedical research that brings together leading researchers, industry innovators, and regulatory stakeholders to shape the future of MPS technologies. Draper is a Gold Sponsor of this year's summit.
"As MPS technologies continue to gain acceptance as robust and predictive New Approach Methodologies (NAMs), the summit provides an important venue for collaboration, knowledge exchange, and progress toward more predictive and human-relevant preclinical models," said Jeffrey Borenstein, Lab Fellow at Draper. "We look forward to connecting with partners and stakeholders to advance the adoption and impact of MPS technologies."
Draper is a leader in microphysiological systems used to model diseases and drug responses. In its 25-year history of MPS development, Draper has pioneered many groundbreaking advances, including long-term culture of mammalian cells in a microfluidic device, the first durable multi-organ system, the first high throughput instrumented MPS, and the first robust and reproducible operation of MPS in high containment.
Draper's Biotechnology Systems team will be available at Booth #723 to discuss the features and benefits of PREDICT96, as well as the many research programs that leverage its capabilities.
In addition, two Draper researcher scientists will deliver presentations at this year's MPS World Summit.
· Christine Fisher will give a contributed talk, "Development of High Throughput, Instrumented Human MPS for High and Maximum Containment," on May 29th at 9 am (Session 2.6).
· Jeff Borenstein will deliver an invited talk, "Development and Demonstration of a Robust and Reproducible Multiplexed Model of Respiratory Infectious Diseases with Real-Time Sensing," on May 29th at 11 am (Session 4.7).
Draper will also present seven posters at this year's summit.
On Wednesday, May 27, 9:30-11:00 am (Poster Session 1):
· Poster #166: A high throughput multi-organ system comprised of an interacting placental barrier and developing heart to assess drug safety during pregnancy
Presenter: Corin Williams
· Poster #174: High throughput immune competent MPS tissue models to study human responses to external threats
Presenter: Anjana Jeyaram
· Poster #188: Circulating leukocytes in MPS models to study immune cell:vascular interactions during damage and infection.
Presenter: Jonathan Coppeta
· Poster #200: Advances in high throughput instrumented MPS for applications in disease modeling and safety and efficacy testing
Presenter: Jeffrey Borenstein
· Poster #208: A scalable and modular multi-organ microphysiological system (ETHOS) for rapid pathogen/toxin characterization and drug development for end-to-end evaluation
Presenter: Ashley Gard
· Poster #308: High-throughput integrated sensors for real-time monitoring of dynamic microphysiological systems
Presenter: Hesham Azizgolshani
On Thursday, May 28, 10:00–11:30 am (Poster Session 3):
· Poster #226: Developing a human vascular microfluidic-based microphysiological system (MPS) model for studying filoviral pathogenesis in maximum containment
Presenter: Christine Fisher
The most consequential challenges in national security and health security demand more than incremental progress. Draper Biotechnology Systems exists to solve these challenges, bringing together elite scientists, engineers, and mission partners to develop next-generation biological systems where failure is not an option.
About Draper
The Charles Stark Draper Laboratory (Draper) is a nonprofit research and development company that focuses on delivering advanced technical solutions for the world’s most challenging and important problems. We leverage our multidisciplinary engineering and biology capabilities to design, develop, and deploy cutting-edge microphysiological systems (MPS) and bioprocessing technologies. Draper has a 25+ year legacy of development of in vitro human tissue systems to improve our understanding of our body and to predict the safety and effectiveness of drugs, vaccines, and medical counter measures. In collaboration with US government and industry, Draper has developed leading organ-on-chip hardware platforms, immune and tissue models, molecular and cellular assays, omics-based technologies, and advanced analytical methods. To learn more about Draper, visit www.draper.com. Follow Draper on Linked In and Instagram.
Released May 20, 2026
